Paper Details

  1. Home
  2. Paper Details

Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.

Author: BarnettAnthony H

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Linagliptin, a dipeptidyl peptidase-4 inhibitor, is generally well tolerated in patients with type 2 diabetes mellitus (T2DM). It improves glycemic control without increasing the risk of hypoglycemia or causing weight gain. It may be a rational alternative treatment option for patients with renal impairment, as it can be used without dose titration.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Established treatments for type 2 diabetes mellitus (T2DM) have side effects that limit their use in specific populations. New therapies with improved safety profiles are needed, especially because of the chronic and progressive nature of T2DM. AREAS COVERED: This review describes the...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14740338.2014.971008

データ提供：米国国立医学図書館（NLM）

Linagliptin for Type 2 Diabetes: A Safer Treatment Option

The world of diabetes treatment is like a vast desert, with many different oases offering relief. This study focuses on linagliptin, a new drug that targets the enzyme dipeptidyl peptidase-4 (DPP-4), which helps regulate blood sugar levels. The authors explore the safety and tolerability of linagliptin, particularly in patients with type 2 diabetes mellitus (T2DM), a challenging condition like navigating a difficult desert landscape.

A Promising Oasis: Linagliptin Offers Improved Safety

The study highlights linagliptin’s favorable safety profile, particularly in patients with renal impairment. This is like discovering a new spring in the desert, providing a safe and effective source of water for those who need it most. Linagliptin is generally well tolerated and does not increase the risk of hypoglycemia or weight gain, offering a more comfortable and effective treatment option for T2DM patients.

Navigating Diabetes Treatment: A New Approach to Care

This research provides valuable insights into the safety and efficacy of linagliptin, a new drug for T2DM. By understanding the benefits and risks of this new treatment, clinicians can make informed decisions to best serve their patients. This discovery, like finding a new path in the desert, offers a more effective and manageable approach to diabetes care.

Dr. Camel's Conclusion

This research explores the potential of linagliptin as a safe and effective treatment for T2DM, particularly for patients with renal impairment. It offers a promising new oasis in the desert of diabetes treatment, providing clinicians with a more manageable and effective approach to caring for their patients.

Date :
  1. Date Completed 2015-09-14
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

25351273

DOI: Digital Object Identifier

10.1517/14740338.2014.971008

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.